What is the maximum duration of taking erdafitinib? Are there any risks in taking it overtime?

Erdafitinib is an oral pan-FGFR inhibitor, mainly used to treat locally advanced or metastatic urothelial carcinoma harboring FGFR2 or FGFR3 mutations. The taking time of this drug varies depending on the individual situation of the patient. It is usually recommended to take 8mg once a day (two 4mg tablets) for 28 days as a cycle. If the patient tolerates the standard dose well and meets the dose adjustment criteria, the doctor may increase the dose to 9 mg per day.

In clinical practice, the treatment cycle of erdafitinib does not have a strict maximum duration. Instead, the decision whether to continue treatment is based on the patient's disease progression, drug efficacy, and tolerance. Some patients can still benefit from the drug after taking it for a long time and will continue to take it under the guidance of their doctor. However, if the disease progresses or intolerable side effects occur, the doctor may recommend suspending or adjusting the dose.

Taking erdafitinib for an extended period of time may increase the risk of adverse reactions, including hyperphosphatemia, vision changes, oral ulcers, hand-foot syndrome, diarrhea, and fatigue. Among them, hyperphosphatemia is a common side effect of erdafitinib. If blood phosphorus levels are too high and not controlled, it may cause cardiovascular or renal problems. In addition, the drug may cause retinopathy, so patients taking it long-term need to have regular eye exams.

Therefore, patients should strictly follow the doctor's instructions when taking erdafitinib and avoid arbitrarily extending or shortening the treatment cycle. If long-term use is necessary, blood phosphate levels, kidney function, liver function, and vision should be monitored regularly to reduce potential risks. If serious adverse reactions occur or drug efficacy decreases, you should communicate with your doctor promptly to adjust the treatment plan or replace it with other feasible treatments.

Reference link:https://www.balversa.com/